Navigation Links
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
Date:5/16/2012

ND with R256.

ATS Poster Presentations
A Randomized, Placebo Controlled Trial of the Effect of an Inhaled SYK Inhibitor on Allergen Induced Airways Responses in Mild Asthma (R343)
May 21, 2012, 8:15AM – 4:30PM
Poster Session: B33 – ASTHMA THERAPY: NOVEL APPROACHES

Janus Kinase (JAK) 3 Inhibitor, R256, Attenuates Allergen-Induced Airway Hyperresponsiveness and Airway Inflammation in Mice
May 21, 2012, 8:15AM – 4:30PM
Poster Session: B33 – ASTHMA THERAPY: NOVEL APPROACHES

R256 Is a Potent and Selective IL13/4 Receptor Signaling Inhibitor That Reduces Inflammation In a Mouse Model of Chronic Asthma
May 21, 2012, 8:15AM – 4:30PM
Poster Session: B37 – NEW INSIGHTS INTO ASTHMA AND COPD TREATMENT

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with our partner AstraZeneca; R343, an inhaled SYK inhibitor that has completed Phase 1 clinical trials for asthma; R333, a topical JAK/SYK inhibitor for discoid lupus; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

This press release contains "forward-looking" statements, including, without limitation, statements related to Rigel's future product candidate pipeline and strategy.  Any statements contained in this pres
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... DIEGO, June 8, 2011 Otonomy, Inc., ... of the ear, today announced positive results for OTO-201, ... in multiple preclinical studies evaluating the treatment of middle ... placement surgery.  Approximately one million tube placement procedures are ...
... NORTH KINGSTOWN, R.I., June 8, 2011 Leading national ... Tufts Health Care Institute,s (THCI) Program on Opioid Risk ... support of THCI,s Program on Opioid Risk Management began ... promoting the safe and effective use of controlled opioid ...
Cached Medicine Technology:Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 2Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 3Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 4Dominion Diagnostics Supports Opioid Risk Management Program for Fourth Consecutive Year 2
(Date:4/24/2014)... Oregon State University researcher has found a relationship between ... of autism spectrum disorder in very young children. ... to show a direct relationship between motor skills and ... motor skills should be included in treatment plans for ... professor in OSU,s College of Public Health and Human ...
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... University researcher is looking to give exercise enthusiasts the ... latest research shows that a cyber buddy can help. ... for Health Journal , is the first to indicate ... motivator during exercise, a software-generated partner also can be ... isn,t real can still motivate people to give greater ...
(Date:4/23/2014)... that targets an important brain receptor has a dramatic ... relapse behavior, a University at Buffalo animal study has ... may be a novel lead compound for treating cocaine ... research was published as an online preview article in ... the compound, RO5263397, severely blunted a broad range of ...
(Date:4/23/2014)... MD (April 23, 2014) The American Gastroenterological ... the 2014 AGA Research Scholars. The AGA Research ... investigators to develop independent and productive research careers ... Scholar Awards fund an additional year allowing for ... committed to supporting junior faculty who are paving ...
Breaking Medicine News(10 mins):Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:AGA announces 2014 Class of AGA Research Scholars 2
... cells within the lung as they move around and ... the causes of Idiopathic Pulmonary Fibrosis (IPF) a disease ... , IPF fills the delicate gas exchange region of ... Duke University Medical Center researchers have discovered that some ...
... --,Americans, awareness of chronic obstructive pulmonary disease (COPD) is rising, ... doctor about symptoms, according to a new survey by the ... COPD -- the third-leading cause of death in the United ... excess sputum production and a feeling of not being able ...
... HealthDay Reporter , THURSDAY, Dec. 1 (HealthDay ... might encourage better shut-eye: People who met national exercise ... those who didn,t. The research doesn,t confirm that ... there may be another explanation for the apparent connection ...
... A diametric shift in the levels of two proteins ... accumulation of the destructive brain plaque found in Alzheimer,s ... folds others into specific positions to unleash their functions. ... it unleashes the normally dormant BACE1, a protein responsible ...
... 2011Researchers have discovered that over a million people worldwide diagnosed ... fungal infection which is usually left untreated because it is ... new report published today in the Bulletin of the ... and University of Toronto say because the X-ray features and ...
... The American Chemical Society,s (ACS,) 243rd National Meeting & Exposition, ... will be held March 25-29, 2012, in San Diego, ... Convention Center and at area hotels. With more than ... from astronomy to zoology ― the meeting will offer print, ...
Cached Medicine News:Health News:New insights come from tracing cells that scar lungs 2Health News:Many Ignore Symptoms of Lung Disease, Study Finds 2Health News:More Exercise Could Make For Better Sleep: Study 2Health News:More Exercise Could Make For Better Sleep: Study 3Health News:Diametric shift in 2 protein levels spurs Alzheimer's plaque accumulation 2Health News:Mistaken identity: New report highlights the global impact of medical misdiagnosis 2
... A wide range of miniTHERM incubators ... the appropriate application solution for their specific ... 18 liters, are compact and extremely space ... typical microwave oven. It is possible to ...
... A wide range of miniTHERM incubators is ... appropriate application solution for their specific requirements. ... liters, are compact and extremely space saving. ... microwave oven. It is possible to stack ...
... resistance of stainless steel with the ... offers an electro-polished copper-alloy-stainless interior that ... sterile environment promotes the integrity of ... safety of laboratory staff. This exclusive ...
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO 2 Inc....
Medicine Products: